Revelation Biosciences In... (REVB)
3.51
-0.03 (-0.85%)
At close: Feb 28, 2025, 3:59 PM
3.33
-5.14%
After-hours: Feb 28, 2025, 04:59 PM EST
No 1D chart data available
| Bid | 3.33 |
| Market Cap | 1.83M |
| Revenue (ttm) | 7.32K |
| Net Income (ttm) | -3.02M |
| EPS (ttm) | -280.48 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.13 |
| Analyst | n/a |
| Ask | 3.65 |
| Volume | 115,330 |
| Avg. Volume (20D) | 243,206 |
| Open | 3.52 |
| Previous Close | 3.54 |
| Day's Range | 3.21 - 3.65 |
| 52-Week Range | 3.19 - 60.80 |
| Beta | 0.19 |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2020
Employees 9
Stock Exchange NASDAQ
Ticker Symbol REVB
Website https://www.revbiosciences.com
1 month ago
-23.84%
Revelation Biosciences shares are trading lower af...
Unlock content with
Pro Subscription
2 months ago
+25%
Revelation Biosciences shares are trading higher after the company announced FDA acceptance of Gemini IND.
2 months ago · businesswire.com
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini INDSAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...